Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 5/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.34 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.32 |
| ▸ | IDE | P14735 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035590 | 0.90 | GCGR (0.36) | PPARDTIPARPHDAC4GCGRL3MBTL1 | |
| SCHEMBL6034691 | 0.89 | SMN1; SMN2 (0.36) | PPARDTIPARPHDAC4GCGRL3MBTL1 | |
| SCHEMBL6036239 | 0.89 | HDAC4 (0.35) | PPARDTIPARPHDAC4GCGRL3MBTL1 | |
| SCHEMBL6034290 | 0.89 | HDAC4 (0.35) | PPARDTIPARPHDAC4GCGRL3MBTL1 | |
| SCHEMBL6035182 | 0.88 | HDAC4 (0.36) | PPARDTIPARPHDAC4GCGRL3MBTL1 | |
| SCHEMBL6035321 | 0.88 | PPARG (0.37) | PPARDTIPARPHDAC4GCGRL3MBTL1 | |
| SCHEMBL6034630 | 0.88 | GCGR (0.34) | PPARDTIPARPHDAC4MGLLGCGR | |
| SCHEMBL1633669 | 0.88 | PPARG (0.43) | PPARDTIPARPHDAC4PPARGSMN1; SMN2 | |
| SCHEMBL6035119 | 0.87 | SMN1; SMN2 (0.40) | PPARDPPARGSMN1; SMN2HPGD | |
| SCHEMBL6035784 | 0.85 | PPARG (0.41) | PPARDTIPARPHDAC4PPARGSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARD 2488/4885SLC6A9 1495/4885TIPARP 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.